- Crystal structures of hBRD2 BD2 with mefenamic acid (ID8) and nimesulide (NIM), and hBRD4 BD1 with NIM, were solved.
- Surface plasmon resonance assays quantitatively confirmed substantial binding of these drugs to hBRD2 and hBRD4 bromodomains.
- SeeSAR-guided derivatives showed improved affinity; molecular dynamics validated stable bromodomain binding, indicating potential hBRD2/hBRD4 inhibitors.
Proteins. 2026 Jul 15. doi: 10.1002/prot.70154. Online ahead of print.
ABSTRACT
The bromodomain and extra-terminal (BET) family of proteins, which regulate chromatin function, is an established potential drug target for treating major diseases such as cancer and inflammatory conditions. There is significant research focused on developing new BET inhibitors with innovative molecular structures to target and modulate the epigenetic mechanisms underlying major diseases, including cancer. Herein, we present the crystal structures of the second bromodomain (BD2) of hBRD2 in complex with the FDA-approved drugs, mefenamic acid (ID8) and nimesulide (NIM), and that of the first bromodomain (BD1) of hBRD4 in complex with nimesulide (NIM). Quantitative binding assays by surface plasmon resonance (SPR) confirmed the substantial binding of these drug molecules to the hBRD2 and hBRD4 bromodomains. Using these crystal structures, a series of ID8 and NIM derivatives with improved affinity relative to the parent compounds was designed and evaluated using SeeSAR (BioSolveIT GmbH). Moreover, molecular dynamics simulations were performed on the selected derivatives of ID8 and NIM against these bromodomains and confirmed the stability of these derivatives’ binding throughout the simulations. We propose that the derivatives of the aforementioned parent molecules may be potential inhibitors of the function of hBRD2 and hBRD4.
PMID:42458221 | DOI:10.1002/prot.70154
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

